Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with a median lifespan of 2–3 years after diagnosis. There are few meaningful treatments that alter progression in this disease. Preclinical and clinical studies have demonstrated that neuroinflammation may play a key role in the progression rate of ALS. Despite this, there are no validated biomarkers of neuroinflammation for use in clinical practice or clinical trials. Biomarkers of neuroinflammation could improve patient management, provide new therapeutic targets, and possibly help stratify clinical trial selection and monitoring. However, attempts to identify a singular cause of neuroinflammation have not been successful. Here, we performed multi-parameter flow cytometry to comprehensively assess 116 leukocyte populations and phenotypes from lymphocytes, monocytes, and granulocytes in a cohort of 80 ALS patients. We identified 32 leukocyte phenotypes that were altered in ALS patients compared to age and gender matched healthy volunteers (HV) that included phenotypes of both inflammation and immune suppression. Unsupervised hierarchical clustering and principle component analysis of ALS and HV immunophenotypes revealed two distinct immune profiles of ALS patients. ALS patients were clustered into a profile distinct from HVs primarily due to differences in a multiple T cell phenotypes, CD3+CD56+ T cells and HLA-DR on monocytes. Patients clustered into an abnormal immune profile were younger, more likely to have a familial form of the disease, and survived longer than those patients who clustered similarly with healthy volunteers (344 weeks versus 184 weeks; p = 0.012). The data set generated from this study establishes an extensive accounting of immunophenotypic changes readily suitable for biomarker validation studies. The extensive immune system changes measured in this study indicate that normal immune homeostatic mechanisms are disrupted in ALS patients, and that multiple immune states likely exist within a population of patients with ALS.

[1]  Bruce D. Johnson,et al.  A systems biology approach to investigating the influence of exercise and fitness on the composition of leukocytes in peripheral blood , 2017, Journal of Immunotherapy for Cancer.

[2]  Stephen A. Goutman,et al.  Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[3]  J. Cheville,et al.  Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma , 2015, Clinical Cancer Research.

[4]  A. Dietz,et al.  A Method for Identification and Analysis of Non-Overlapping Myeloid Immunophenotypes in Humans , 2015, PloS one.

[5]  S. Amor,et al.  Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. , 2015, International immunology.

[6]  M. Schwartz,et al.  Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: boosting autoimmunity to fight-off chronic neuroinflammation. , 2014, Journal of autoimmunity.

[7]  A. Dietz,et al.  Strategies for improving the reporting of human immunophenotypes by flow cytometry , 2014, Journal of Immunotherapy for Cancer.

[8]  A. Dietz,et al.  Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14+HLA-DRlo/neg Cells): The Gateway to Improved Responses , 2014, Front. Immunol..

[9]  S. Appel,et al.  Immune-mediated Mechanisms in the Pathoprogression of Amyotrophic Lateral Sclerosis , 2013, Journal of Neuroimmune Pharmacology.

[10]  A. Dietz,et al.  Immune monitoring using the predictive power of immune profiles , 2013, Journal of Immunotherapy for Cancer.

[11]  S. Powell,et al.  Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival , 2012, EMBO molecular medicine.

[12]  H. Weiner,et al.  Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. , 2012, The Journal of clinical investigation.

[13]  I. Evdokimidis,et al.  Alterations of T cell subsets in ALS: a systemic immune activation? , 2012, Acta neurologica Scandinavica.

[14]  L. Moretta,et al.  Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. , 2011, Blood.

[15]  S. Appel,et al.  Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice , 2011, Brain, Behavior, and Immunity.

[16]  M. Uhrberg,et al.  IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion. , 2011, Immunobiology.

[17]  W. Robberecht,et al.  Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease , 2011, The Lancet Neurology.

[18]  A. Dietz,et al.  Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. , 2011, Blood.

[19]  Silvano Sozzani,et al.  Nomenclature of monocytes and dendritic cells in blood. , 2010, Blood.

[20]  Yi Lin,et al.  Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. , 2010, Neuro-oncology.

[21]  G. Mora,et al.  Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process , 2009, Journal of Neuroimmunology.

[22]  M. Introna,et al.  Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. , 2009, Experimental hematology.

[23]  P. Leigh,et al.  Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[24]  H. Heslop,et al.  Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis , 2008, Neurology.

[25]  S. Appel,et al.  CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS , 2008, Proceedings of the National Academy of Sciences.

[26]  T. Holmøy,et al.  T cells in amyotrophic lateral sclerosis , 2008, European journal of neurology.

[27]  D. Gutmann,et al.  Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis , 2008, Nature Neuroscience.

[28]  S. Studenski,et al.  Induction of CD56 and TCR-Independent Activation of T Cells with Aging1 , 2008, The Journal of Immunology.

[29]  H. Mitsumoto,et al.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial , 2007, The Lancet Neurology.

[30]  D. Doherty,et al.  Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro. , 2006, Human immunology.

[31]  D. Schoenfeld,et al.  Trial of celecoxib in amyotrophic lateral sclerosis , 2006, Annals of neurology.

[32]  G. Kollias,et al.  Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia , 2006, Science.

[33]  Lan Guo,et al.  Development of rabbit monoclonal and polyclonal antibodies for detection of site-specific histone modifications and their application in analyzing overall modification levels , 2006, Cell Research.

[34]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[35]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[36]  J. Cedarbaum,et al.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.

[37]  J. Tajti,et al.  Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. , 1993, Archives of neurology.